Status:

COMPLETED

PK Study of Tacrolimus and Cyclosporine When Co-Administered With Adefovir Dipivoxil in Post-Liver Transplant Patients

Lead Sponsor:

Gilead Sciences

Conditions:

Hepatitis B

Eligibility:

All Genders

18-65 years

Phase:

PHASE2

Brief Summary

Open-label pharmacokinetic drug interaction study.

Detailed Description

Multi-center, phase 2, open-label, sequential-cohort, drug interaction study. Cohort 1 subjects (tacrolimus and adefovir dipivoxil) were enrolled first. Based on the findings in Cohort 1, a decision w...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • 18-65 years of age
  • Greater than or equal to 6 months post-liver transplantation
  • Must be on a documented stable total daily dose of tacrolimus or cyclosporine for three months.
  • Must have calculated creatinine clearance greater than or equal 50 mL/min (Cockcroft-Gault method).

Exclusion

    Key Trial Info

    Start Date :

    February 1 2004

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    May 1 2005

    Estimated Enrollment :

    16 Patients enrolled

    Trial Details

    Trial ID

    NCT00644761

    Start Date

    February 1 2004

    End Date

    May 1 2005

    Last Update

    April 10 2008

    Active Locations (11)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 3 (11 locations)

    1

    University of Alabama at Birmingham

    Birmingham, Alabama, United States, 35294

    2

    Cedars Sinai Medical Center

    Los Angeles, California, United States, 90048

    3

    California Pacific Medical Center

    San Francisco, California, United States, 94115

    4

    University of California, San Francisco

    San Francisco, California, United States, 94143

    PK Study of Tacrolimus and Cyclosporine When Co-Administered With Adefovir Dipivoxil in Post-Liver Transplant Patients | DecenTrialz